Group leader
Principal investigators
Overview
The research of the Experimental Therapeutics Group (ETG) focuses on the discovery
and development of novel small molecule anticancer drugs, with interests spanning
all aspects of the drug development pipeline from target validation to early phase
clinical trials. Our main emphasis is on exploiting abnormalities in the tumour
microenvironment, such as hypoxia, that arise because of an inefficient vascular
supply. A major interest is the development of prodrugs that are
activated locally
within tumours, either through metabolism by endogenous enzymes under hypoxia or
through the introduction of exogenous drug-metabolising enzymes. Our drug discovery
projects are in collaboration with the
Medicinal Chemistry Group. The ETG
also has a strong interest in the diffusion of anticancer agents and their active
metabolites in tumour tissue, which is an important and neglected problem in cancer
pharmacology.
Medicinal Chemistry Group
Current
research projects
